Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate
--Phase 1 clinical trial will evaluate safety and immunogenicity of several formulations of SCB-2020S as a 2-dose vaccination series in...